Biovica International AB Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
Sales 2024 * | 10M 949K | Sales 2025 * | 116M 11.01M | Capitalization | 151M 14.36M |
---|---|---|---|---|---|
Net income 2024 * | -115M -10.92M | Net income 2025 * | -60M -5.7M | EV / Sales 2024 * | 7.78 x |
Net cash position 2024 * | 73.52M 6.98M | Net cash position 2025 * | 45.95M 4.36M | EV / Sales 2025 * | 0.91 x |
P/E ratio 2024 * |
-0.24
x | P/E ratio 2025 * |
-0.63
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.54% |
Latest transcript on Biovica International AB
Managers | Title | Age | Since |
---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 09-12-31 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 22-12-31 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 64 | 19-03-19 | |
Annika Berg
BRD | Director/Board Member | 61 | 19-12-31 |
Maria Holmlund
BRD | Director/Board Member | 68 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-32.63% | 9.2B | |
-5.66% | 3.12B | |
+23.12% | 2.8B | |
-17.75% | 2.07B | |
-24.39% | 1.59B | |
+65.65% | 1.44B | |
+32.83% | 830M | |
-6.55% | 724M | |
-29.80% | 507M |